nodes	percent_of_prediction	percent_of_DWPC	metapath
Midodrine—CYP2D6—Lomustine—hematologic cancer	0.0767	0.189	CbGbCtD
Midodrine—CYP2D6—Idarubicin—hematologic cancer	0.0684	0.168	CbGbCtD
Midodrine—CYP2D6—Hydroxyurea—hematologic cancer	0.0582	0.143	CbGbCtD
Midodrine—CYP2D6—Bortezomib—hematologic cancer	0.0506	0.124	CbGbCtD
Midodrine—CYP2D6—Imatinib—hematologic cancer	0.0371	0.0912	CbGbCtD
Midodrine—CYP2D6—Nilotinib—hematologic cancer	0.0337	0.0829	CbGbCtD
Midodrine—CYP2D6—Vinorelbine—hematologic cancer	0.0334	0.0822	CbGbCtD
Midodrine—CYP2D6—Vinblastine—hematologic cancer	0.0206	0.0506	CbGbCtD
Midodrine—CYP2D6—Dexamethasone—hematologic cancer	0.0152	0.0375	CbGbCtD
Midodrine—CYP2D6—Doxorubicin—hematologic cancer	0.0126	0.0311	CbGbCtD
Midodrine—Melatonin—CALR—hematologic cancer	0.00674	0.744	CrCbGaD
Midodrine—Melatonin—MPO—hematologic cancer	0.00132	0.146	CrCbGaD
Midodrine—Melatonin—ESR1—hematologic cancer	0.000993	0.11	CrCbGaD
Midodrine—Nausea—Vinorelbine—hematologic cancer	0.000174	0.000345	CcSEcCtD
Midodrine—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000174	0.000344	CcSEcCtD
Midodrine—Asthenia—Irinotecan—hematologic cancer	0.000174	0.000344	CcSEcCtD
Midodrine—Asthenia—Mitoxantrone—hematologic cancer	0.000174	0.000344	CcSEcCtD
Midodrine—Stomatitis—Epirubicin—hematologic cancer	0.000173	0.000341	CcSEcCtD
Midodrine—Anxiety—Betamethasone—hematologic cancer	0.000172	0.000341	CcSEcCtD
Midodrine—Anxiety—Dexamethasone—hematologic cancer	0.000172	0.000341	CcSEcCtD
Midodrine—Dizziness—Carmustine—hematologic cancer	0.000172	0.000341	CcSEcCtD
Midodrine—Pain—Etoposide—hematologic cancer	0.000172	0.000341	CcSEcCtD
Midodrine—Dysuria—Doxorubicin—hematologic cancer	0.000172	0.00034	CcSEcCtD
Midodrine—Rash—Thalidomide—hematologic cancer	0.000171	0.000338	CcSEcCtD
Midodrine—Dermatitis—Thalidomide—hematologic cancer	0.000171	0.000338	CcSEcCtD
Midodrine—Dizziness—Alitretinoin—hematologic cancer	0.000171	0.000338	CcSEcCtD
Midodrine—Headache—Thalidomide—hematologic cancer	0.00017	0.000336	CcSEcCtD
Midodrine—Pain—Prednisolone—hematologic cancer	0.00017	0.000336	CcSEcCtD
Midodrine—Pollakiuria—Doxorubicin—hematologic cancer	0.00017	0.000336	CcSEcCtD
Midodrine—Asthenia—Gemcitabine—hematologic cancer	0.000169	0.000335	CcSEcCtD
Midodrine—Dizziness—Ifosfamide—hematologic cancer	0.000169	0.000334	CcSEcCtD
Midodrine—Urinary tract disorder—Methotrexate—hematologic cancer	0.000168	0.000332	CcSEcCtD
Midodrine—Hepatobiliary disease—Epirubicin—hematologic cancer	0.000167	0.000331	CcSEcCtD
Midodrine—Pruritus—Gemcitabine—hematologic cancer	0.000167	0.00033	CcSEcCtD
Midodrine—Nausea—Thiotepa—hematologic cancer	0.000167	0.00033	CcSEcCtD
Midodrine—Urethral disorder—Methotrexate—hematologic cancer	0.000167	0.000329	CcSEcCtD
Midodrine—Feeling abnormal—Etoposide—hematologic cancer	0.000166	0.000328	CcSEcCtD
Midodrine—Insomnia—Triamcinolone—hematologic cancer	0.000165	0.000327	CcSEcCtD
Midodrine—Gastrointestinal pain—Etoposide—hematologic cancer	0.000165	0.000326	CcSEcCtD
Midodrine—Dizziness—Vincristine—hematologic cancer	0.000164	0.000325	CcSEcCtD
Midodrine—Rash—Carmustine—hematologic cancer	0.000164	0.000325	CcSEcCtD
Midodrine—Dermatitis—Carmustine—hematologic cancer	0.000164	0.000325	CcSEcCtD
Midodrine—Paraesthesia—Triamcinolone—hematologic cancer	0.000164	0.000325	CcSEcCtD
Midodrine—Feeling abnormal—Prednisolone—hematologic cancer	0.000164	0.000324	CcSEcCtD
Midodrine—Headache—Carmustine—hematologic cancer	0.000163	0.000323	CcSEcCtD
Midodrine—Dyspnoea—Triamcinolone—hematologic cancer	0.000163	0.000322	CcSEcCtD
Midodrine—Rash—Alitretinoin—hematologic cancer	0.000163	0.000322	CcSEcCtD
Midodrine—Nervous system disorder—Dexamethasone—hematologic cancer	0.000163	0.000322	CcSEcCtD
Midodrine—Nervous system disorder—Betamethasone—hematologic cancer	0.000163	0.000322	CcSEcCtD
Midodrine—Agitation—Prednisone—hematologic cancer	0.000163	0.000322	CcSEcCtD
Midodrine—Dermatitis—Alitretinoin—hematologic cancer	0.000163	0.000322	CcSEcCtD
Midodrine—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	0.000162	0.000321	CcSEcCtD
Midodrine—Tachycardia—Betamethasone—hematologic cancer	0.000162	0.00032	CcSEcCtD
Midodrine—Tachycardia—Dexamethasone—hematologic cancer	0.000162	0.00032	CcSEcCtD
Midodrine—Bradycardia—Epirubicin—hematologic cancer	0.000162	0.00032	CcSEcCtD
Midodrine—Headache—Alitretinoin—hematologic cancer	0.000162	0.00032	CcSEcCtD
Midodrine—Nausea—Thalidomide—hematologic cancer	0.000161	0.000319	CcSEcCtD
Midodrine—Dyspepsia—Triamcinolone—hematologic cancer	0.000161	0.000318	CcSEcCtD
Midodrine—Rash—Ifosfamide—hematologic cancer	0.000161	0.000318	CcSEcCtD
Midodrine—Dermatitis—Ifosfamide—hematologic cancer	0.000161	0.000318	CcSEcCtD
Midodrine—Erythema multiforme—Methotrexate—hematologic cancer	0.000161	0.000318	CcSEcCtD
Midodrine—Dizziness—Irinotecan—hematologic cancer	0.00016	0.000317	CcSEcCtD
Midodrine—Stomatitis—Doxorubicin—hematologic cancer	0.00016	0.000316	CcSEcCtD
Midodrine—Abdominal pain—Etoposide—hematologic cancer	0.000159	0.000315	CcSEcCtD
Midodrine—Asthenia—Cisplatin—hematologic cancer	0.000158	0.000312	CcSEcCtD
Midodrine—Cardiac disorder—Methotrexate—hematologic cancer	0.000158	0.000312	CcSEcCtD
Midodrine—Urinary tract disorder—Epirubicin—hematologic cancer	0.000157	0.000311	CcSEcCtD
Midodrine—Rash—Vincristine—hematologic cancer	0.000157	0.00031	CcSEcCtD
Midodrine—Dermatitis—Vincristine—hematologic cancer	0.000157	0.00031	CcSEcCtD
Midodrine—Pain—Triamcinolone—hematologic cancer	0.000156	0.000309	CcSEcCtD
Midodrine—Urethral disorder—Epirubicin—hematologic cancer	0.000156	0.000308	CcSEcCtD
Midodrine—Headache—Vincristine—hematologic cancer	0.000156	0.000308	CcSEcCtD
Midodrine—Hepatobiliary disease—Doxorubicin—hematologic cancer	0.000155	0.000307	CcSEcCtD
Midodrine—Nausea—Carmustine—hematologic cancer	0.000155	0.000306	CcSEcCtD
Midodrine—Angiopathy—Methotrexate—hematologic cancer	0.000154	0.000305	CcSEcCtD
Midodrine—Nausea—Alitretinoin—hematologic cancer	0.000153	0.000303	CcSEcCtD
Midodrine—Hypertension—Prednisone—hematologic cancer	0.000153	0.000302	CcSEcCtD
Midodrine—Rash—Irinotecan—hematologic cancer	0.000153	0.000302	CcSEcCtD
Midodrine—Rash—Mitoxantrone—hematologic cancer	0.000153	0.000302	CcSEcCtD
Midodrine—Dermatitis—Irinotecan—hematologic cancer	0.000153	0.000302	CcSEcCtD
Midodrine—Dermatitis—Mitoxantrone—hematologic cancer	0.000153	0.000302	CcSEcCtD
Midodrine—Chills—Methotrexate—hematologic cancer	0.000152	0.000302	CcSEcCtD
Midodrine—Headache—Irinotecan—hematologic cancer	0.000152	0.0003	CcSEcCtD
Midodrine—Headache—Mitoxantrone—hematologic cancer	0.000152	0.0003	CcSEcCtD
Midodrine—Nausea—Ifosfamide—hematologic cancer	0.000152	0.0003	CcSEcCtD
Midodrine—Feeling abnormal—Triamcinolone—hematologic cancer	0.000151	0.000298	CcSEcCtD
Midodrine—Erythema multiforme—Epirubicin—hematologic cancer	0.00015	0.000297	CcSEcCtD
Midodrine—Anxiety—Prednisone—hematologic cancer	0.00015	0.000297	CcSEcCtD
Midodrine—Insomnia—Dexamethasone—hematologic cancer	0.00015	0.000297	CcSEcCtD
Midodrine—Insomnia—Betamethasone—hematologic cancer	0.00015	0.000297	CcSEcCtD
Midodrine—Bradycardia—Doxorubicin—hematologic cancer	0.00015	0.000296	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.00015	0.000296	CcSEcCtD
Midodrine—Paraesthesia—Dexamethasone—hematologic cancer	0.000149	0.000295	CcSEcCtD
Midodrine—Paraesthesia—Betamethasone—hematologic cancer	0.000149	0.000295	CcSEcCtD
Midodrine—Mental disorder—Methotrexate—hematologic cancer	0.000149	0.000294	CcSEcCtD
Midodrine—Rash—Gemcitabine—hematologic cancer	0.000149	0.000294	CcSEcCtD
Midodrine—Dermatitis—Gemcitabine—hematologic cancer	0.000149	0.000294	CcSEcCtD
Midodrine—Headache—Gemcitabine—hematologic cancer	0.000148	0.000292	CcSEcCtD
Midodrine—Nausea—Vincristine—hematologic cancer	0.000148	0.000292	CcSEcCtD
Midodrine—Flushing—Epirubicin—hematologic cancer	0.000148	0.000292	CcSEcCtD
Midodrine—Cardiac disorder—Epirubicin—hematologic cancer	0.000148	0.000292	CcSEcCtD
Midodrine—Dyspepsia—Betamethasone—hematologic cancer	0.000146	0.000289	CcSEcCtD
Midodrine—Dyspepsia—Dexamethasone—hematologic cancer	0.000146	0.000289	CcSEcCtD
Midodrine—Urinary tract disorder—Doxorubicin—hematologic cancer	0.000145	0.000287	CcSEcCtD
Midodrine—Asthenia—Etoposide—hematologic cancer	0.000145	0.000286	CcSEcCtD
Midodrine—Angiopathy—Epirubicin—hematologic cancer	0.000144	0.000285	CcSEcCtD
Midodrine—Urethral disorder—Doxorubicin—hematologic cancer	0.000144	0.000285	CcSEcCtD
Midodrine—Nausea—Irinotecan—hematologic cancer	0.000144	0.000285	CcSEcCtD
Midodrine—Nausea—Mitoxantrone—hematologic cancer	0.000144	0.000285	CcSEcCtD
Midodrine—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000143	0.000283	CcSEcCtD
Midodrine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000143	0.000283	CcSEcCtD
Midodrine—Back pain—Methotrexate—hematologic cancer	0.000143	0.000283	CcSEcCtD
Midodrine—Chills—Epirubicin—hematologic cancer	0.000143	0.000282	CcSEcCtD
Midodrine—Pruritus—Etoposide—hematologic cancer	0.000143	0.000282	CcSEcCtD
Midodrine—Pain—Dexamethasone—hematologic cancer	0.000142	0.000281	CcSEcCtD
Midodrine—Pain—Betamethasone—hematologic cancer	0.000142	0.000281	CcSEcCtD
Midodrine—Nervous system disorder—Prednisone—hematologic cancer	0.000142	0.00028	CcSEcCtD
Midodrine—Tachycardia—Prednisone—hematologic cancer	0.000141	0.000279	CcSEcCtD
Midodrine—Skin disorder—Prednisone—hematologic cancer	0.00014	0.000277	CcSEcCtD
Midodrine—Nausea—Gemcitabine—hematologic cancer	0.00014	0.000277	CcSEcCtD
Midodrine—Mental disorder—Epirubicin—hematologic cancer	0.000139	0.000276	CcSEcCtD
Midodrine—Erythema multiforme—Doxorubicin—hematologic cancer	0.000139	0.000275	CcSEcCtD
Midodrine—Rash—Cisplatin—hematologic cancer	0.000139	0.000274	CcSEcCtD
Midodrine—Dermatitis—Cisplatin—hematologic cancer	0.000139	0.000274	CcSEcCtD
Midodrine—Feeling abnormal—Betamethasone—hematologic cancer	0.000137	0.00027	CcSEcCtD
Midodrine—Feeling abnormal—Dexamethasone—hematologic cancer	0.000137	0.00027	CcSEcCtD
Midodrine—Cardiac disorder—Doxorubicin—hematologic cancer	0.000137	0.00027	CcSEcCtD
Midodrine—Flushing—Doxorubicin—hematologic cancer	0.000137	0.00027	CcSEcCtD
Midodrine—Flatulence—Epirubicin—hematologic cancer	0.000136	0.00027	CcSEcCtD
Midodrine—Tension—Epirubicin—hematologic cancer	0.000136	0.000269	CcSEcCtD
Midodrine—Gastrointestinal pain—Betamethasone—hematologic cancer	0.000136	0.000268	CcSEcCtD
Midodrine—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.000136	0.000268	CcSEcCtD
Midodrine—Nervousness—Epirubicin—hematologic cancer	0.000134	0.000266	CcSEcCtD
Midodrine—Back pain—Epirubicin—hematologic cancer	0.000134	0.000265	CcSEcCtD
Midodrine—Angiopathy—Doxorubicin—hematologic cancer	0.000133	0.000264	CcSEcCtD
Midodrine—Dizziness—Etoposide—hematologic cancer	0.000133	0.000264	CcSEcCtD
Midodrine—Muscle spasms—Epirubicin—hematologic cancer	0.000133	0.000263	CcSEcCtD
Midodrine—Chills—Doxorubicin—hematologic cancer	0.000132	0.000261	CcSEcCtD
Midodrine—Dizziness—Prednisolone—hematologic cancer	0.000131	0.00026	CcSEcCtD
Midodrine—Asthenia—Triamcinolone—hematologic cancer	0.000131	0.000259	CcSEcCtD
Midodrine—Abdominal pain—Dexamethasone—hematologic cancer	0.000131	0.000259	CcSEcCtD
Midodrine—Abdominal pain—Betamethasone—hematologic cancer	0.000131	0.000259	CcSEcCtD
Midodrine—Nausea—Cisplatin—hematologic cancer	0.000131	0.000258	CcSEcCtD
Midodrine—Insomnia—Prednisone—hematologic cancer	0.000131	0.000258	CcSEcCtD
Midodrine—Paraesthesia—Prednisone—hematologic cancer	0.00013	0.000257	CcSEcCtD
Midodrine—Pruritus—Triamcinolone—hematologic cancer	0.000129	0.000256	CcSEcCtD
Midodrine—Mental disorder—Doxorubicin—hematologic cancer	0.000129	0.000255	CcSEcCtD
Midodrine—Agitation—Epirubicin—hematologic cancer	0.000127	0.000252	CcSEcCtD
Midodrine—Dyspepsia—Prednisone—hematologic cancer	0.000127	0.000251	CcSEcCtD
Midodrine—Rash—Etoposide—hematologic cancer	0.000127	0.000251	CcSEcCtD
Midodrine—Dermatitis—Etoposide—hematologic cancer	0.000127	0.000251	CcSEcCtD
Midodrine—Headache—Etoposide—hematologic cancer	0.000126	0.00025	CcSEcCtD
Midodrine—Flatulence—Doxorubicin—hematologic cancer	0.000126	0.00025	CcSEcCtD
Midodrine—Tension—Doxorubicin—hematologic cancer	0.000126	0.000249	CcSEcCtD
Midodrine—Rash—Prednisolone—hematologic cancer	0.000125	0.000248	CcSEcCtD
Midodrine—Dermatitis—Prednisolone—hematologic cancer	0.000125	0.000248	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	0.000125	0.000247	CcSEcCtD
Midodrine—Headache—Prednisolone—hematologic cancer	0.000124	0.000246	CcSEcCtD
Midodrine—Nervousness—Doxorubicin—hematologic cancer	0.000124	0.000246	CcSEcCtD
Midodrine—Back pain—Doxorubicin—hematologic cancer	0.000124	0.000245	CcSEcCtD
Midodrine—Muscle spasms—Doxorubicin—hematologic cancer	0.000123	0.000244	CcSEcCtD
Midodrine—Confusional state—Methotrexate—hematologic cancer	0.000122	0.000241	CcSEcCtD
Midodrine—Dizziness—Triamcinolone—hematologic cancer	0.000121	0.000239	CcSEcCtD
Midodrine—Nausea—Etoposide—hematologic cancer	0.00012	0.000237	CcSEcCtD
Midodrine—Hypertension—Epirubicin—hematologic cancer	0.000119	0.000236	CcSEcCtD
Midodrine—Feeling abnormal—Prednisone—hematologic cancer	0.000119	0.000235	CcSEcCtD
Midodrine—Asthenia—Betamethasone—hematologic cancer	0.000119	0.000235	CcSEcCtD
Midodrine—Asthenia—Dexamethasone—hematologic cancer	0.000119	0.000235	CcSEcCtD
Midodrine—Nervous system disorder—Methotrexate—hematologic cancer	0.000118	0.000234	CcSEcCtD
Midodrine—Gastrointestinal pain—Prednisone—hematologic cancer	0.000118	0.000234	CcSEcCtD
Midodrine—Nausea—Prednisolone—hematologic cancer	0.000118	0.000234	CcSEcCtD
Midodrine—Agitation—Doxorubicin—hematologic cancer	0.000118	0.000233	CcSEcCtD
Midodrine—Anxiety—Epirubicin—hematologic cancer	0.000117	0.000232	CcSEcCtD
Midodrine—Pruritus—Dexamethasone—hematologic cancer	0.000117	0.000232	CcSEcCtD
Midodrine—Pruritus—Betamethasone—hematologic cancer	0.000117	0.000232	CcSEcCtD
Midodrine—Skin disorder—Methotrexate—hematologic cancer	0.000117	0.000232	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	0.000117	0.000231	CcSEcCtD
Midodrine—Rash—Triamcinolone—hematologic cancer	0.000115	0.000228	CcSEcCtD
Midodrine—Dry mouth—Epirubicin—hematologic cancer	0.000115	0.000228	CcSEcCtD
Midodrine—Dermatitis—Triamcinolone—hematologic cancer	0.000115	0.000228	CcSEcCtD
Midodrine—Headache—Triamcinolone—hematologic cancer	0.000114	0.000226	CcSEcCtD
Midodrine—Abdominal pain—Prednisone—hematologic cancer	0.000114	0.000226	CcSEcCtD
Midodrine—Confusional state—Epirubicin—hematologic cancer	0.000114	0.000225	CcSEcCtD
Midodrine—Nervous system disorder—Epirubicin—hematologic cancer	0.000111	0.000219	CcSEcCtD
Midodrine—Hypertension—Doxorubicin—hematologic cancer	0.000111	0.000219	CcSEcCtD
Midodrine—Tachycardia—Epirubicin—hematologic cancer	0.00011	0.000218	CcSEcCtD
Midodrine—Skin disorder—Epirubicin—hematologic cancer	0.00011	0.000217	CcSEcCtD
Midodrine—Dizziness—Betamethasone—hematologic cancer	0.00011	0.000217	CcSEcCtD
Midodrine—Dizziness—Dexamethasone—hematologic cancer	0.00011	0.000217	CcSEcCtD
Midodrine—Insomnia—Methotrexate—hematologic cancer	0.000109	0.000216	CcSEcCtD
Midodrine—Anxiety—Doxorubicin—hematologic cancer	0.000109	0.000215	CcSEcCtD
Midodrine—Nausea—Triamcinolone—hematologic cancer	0.000109	0.000215	CcSEcCtD
Midodrine—Paraesthesia—Methotrexate—hematologic cancer	0.000108	0.000214	CcSEcCtD
Midodrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	0.000108	0.000214	CcSEcCtD
Midodrine—Dyspnoea—Methotrexate—hematologic cancer	0.000108	0.000213	CcSEcCtD
Midodrine—Somnolence—Methotrexate—hematologic cancer	0.000107	0.000212	CcSEcCtD
Midodrine—Dry mouth—Doxorubicin—hematologic cancer	0.000107	0.000211	CcSEcCtD
Midodrine—Dyspepsia—Methotrexate—hematologic cancer	0.000106	0.00021	CcSEcCtD
Midodrine—Confusional state—Doxorubicin—hematologic cancer	0.000105	0.000208	CcSEcCtD
Midodrine—Rash—Betamethasone—hematologic cancer	0.000105	0.000207	CcSEcCtD
Midodrine—Rash—Dexamethasone—hematologic cancer	0.000105	0.000207	CcSEcCtD
Midodrine—Dermatitis—Betamethasone—hematologic cancer	0.000104	0.000207	CcSEcCtD
Midodrine—Dermatitis—Dexamethasone—hematologic cancer	0.000104	0.000207	CcSEcCtD
Midodrine—Gastrointestinal disorder—Methotrexate—hematologic cancer	0.000104	0.000206	CcSEcCtD
Midodrine—Headache—Betamethasone—hematologic cancer	0.000104	0.000206	CcSEcCtD
Midodrine—Headache—Dexamethasone—hematologic cancer	0.000104	0.000206	CcSEcCtD
Midodrine—Asthenia—Prednisone—hematologic cancer	0.000104	0.000205	CcSEcCtD
Midodrine—Pain—Methotrexate—hematologic cancer	0.000103	0.000204	CcSEcCtD
Midodrine—Nervous system disorder—Doxorubicin—hematologic cancer	0.000102	0.000203	CcSEcCtD
Midodrine—Pruritus—Prednisone—hematologic cancer	0.000102	0.000202	CcSEcCtD
Midodrine—Insomnia—Epirubicin—hematologic cancer	0.000102	0.000202	CcSEcCtD
Midodrine—Tachycardia—Doxorubicin—hematologic cancer	0.000102	0.000202	CcSEcCtD
Midodrine—Skin disorder—Doxorubicin—hematologic cancer	0.000102	0.000201	CcSEcCtD
Midodrine—Paraesthesia—Epirubicin—hematologic cancer	0.000101	0.000201	CcSEcCtD
Midodrine—Dyspnoea—Epirubicin—hematologic cancer	0.000101	0.000199	CcSEcCtD
Midodrine—Somnolence—Epirubicin—hematologic cancer	0.0001	0.000199	CcSEcCtD
Midodrine—Feeling abnormal—Methotrexate—hematologic cancer	9.95e-05	0.000197	CcSEcCtD
Midodrine—Dyspepsia—Epirubicin—hematologic cancer	9.94e-05	0.000197	CcSEcCtD
Midodrine—Gastrointestinal pain—Methotrexate—hematologic cancer	9.87e-05	0.000195	CcSEcCtD
Midodrine—Nausea—Betamethasone—hematologic cancer	9.85e-05	0.000195	CcSEcCtD
Midodrine—Nausea—Dexamethasone—hematologic cancer	9.85e-05	0.000195	CcSEcCtD
Midodrine—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.75e-05	0.000193	CcSEcCtD
Midodrine—Pain—Epirubicin—hematologic cancer	9.66e-05	0.000191	CcSEcCtD
Midodrine—Dizziness—Prednisone—hematologic cancer	9.55e-05	0.000189	CcSEcCtD
Midodrine—Abdominal pain—Methotrexate—hematologic cancer	9.54e-05	0.000189	CcSEcCtD
Midodrine—Insomnia—Doxorubicin—hematologic cancer	9.45e-05	0.000187	CcSEcCtD
Midodrine—Paraesthesia—Doxorubicin—hematologic cancer	9.38e-05	0.000186	CcSEcCtD
Midodrine—Dyspnoea—Doxorubicin—hematologic cancer	9.32e-05	0.000184	CcSEcCtD
Midodrine—Feeling abnormal—Epirubicin—hematologic cancer	9.31e-05	0.000184	CcSEcCtD
Midodrine—Somnolence—Doxorubicin—hematologic cancer	9.29e-05	0.000184	CcSEcCtD
Midodrine—Gastrointestinal pain—Epirubicin—hematologic cancer	9.24e-05	0.000183	CcSEcCtD
Midodrine—Dyspepsia—Doxorubicin—hematologic cancer	9.2e-05	0.000182	CcSEcCtD
Midodrine—Rash—Prednisone—hematologic cancer	9.11e-05	0.00018	CcSEcCtD
Midodrine—Dermatitis—Prednisone—hematologic cancer	9.1e-05	0.00018	CcSEcCtD
Midodrine—Headache—Prednisone—hematologic cancer	9.05e-05	0.000179	CcSEcCtD
Midodrine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.02e-05	0.000178	CcSEcCtD
Midodrine—Pain—Doxorubicin—hematologic cancer	8.94e-05	0.000177	CcSEcCtD
Midodrine—Abdominal pain—Epirubicin—hematologic cancer	8.93e-05	0.000177	CcSEcCtD
Midodrine—Asthenia—Methotrexate—hematologic cancer	8.66e-05	0.000171	CcSEcCtD
Midodrine—Feeling abnormal—Doxorubicin—hematologic cancer	8.61e-05	0.00017	CcSEcCtD
Midodrine—Nausea—Prednisone—hematologic cancer	8.58e-05	0.00017	CcSEcCtD
Midodrine—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.55e-05	0.000169	CcSEcCtD
Midodrine—Pruritus—Methotrexate—hematologic cancer	8.54e-05	0.000169	CcSEcCtD
Midodrine—Abdominal pain—Doxorubicin—hematologic cancer	8.26e-05	0.000163	CcSEcCtD
Midodrine—Asthenia—Epirubicin—hematologic cancer	8.1e-05	0.00016	CcSEcCtD
Midodrine—Pruritus—Epirubicin—hematologic cancer	7.99e-05	0.000158	CcSEcCtD
Midodrine—Dizziness—Methotrexate—hematologic cancer	7.98e-05	0.000158	CcSEcCtD
Midodrine—Rash—Methotrexate—hematologic cancer	7.61e-05	0.000151	CcSEcCtD
Midodrine—Dermatitis—Methotrexate—hematologic cancer	7.6e-05	0.00015	CcSEcCtD
Midodrine—Headache—Methotrexate—hematologic cancer	7.56e-05	0.00015	CcSEcCtD
Midodrine—Asthenia—Doxorubicin—hematologic cancer	7.5e-05	0.000148	CcSEcCtD
Midodrine—Dizziness—Epirubicin—hematologic cancer	7.47e-05	0.000148	CcSEcCtD
Midodrine—Pruritus—Doxorubicin—hematologic cancer	7.39e-05	0.000146	CcSEcCtD
Midodrine—Nausea—Methotrexate—hematologic cancer	7.17e-05	0.000142	CcSEcCtD
Midodrine—Rash—Epirubicin—hematologic cancer	7.12e-05	0.000141	CcSEcCtD
Midodrine—Dermatitis—Epirubicin—hematologic cancer	7.11e-05	0.000141	CcSEcCtD
Midodrine—Headache—Epirubicin—hematologic cancer	7.08e-05	0.00014	CcSEcCtD
Midodrine—Dizziness—Doxorubicin—hematologic cancer	6.91e-05	0.000137	CcSEcCtD
Midodrine—Nausea—Epirubicin—hematologic cancer	6.71e-05	0.000133	CcSEcCtD
Midodrine—Rash—Doxorubicin—hematologic cancer	6.59e-05	0.00013	CcSEcCtD
Midodrine—Dermatitis—Doxorubicin—hematologic cancer	6.58e-05	0.00013	CcSEcCtD
Midodrine—Headache—Doxorubicin—hematologic cancer	6.55e-05	0.00013	CcSEcCtD
Midodrine—Nausea—Doxorubicin—hematologic cancer	6.21e-05	0.000123	CcSEcCtD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CD—hematologic cancer	1.6e-05	0.000202	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL2RA—hematologic cancer	1.59e-05	0.000201	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL2—hematologic cancer	1.58e-05	0.0002	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STAT5A—hematologic cancer	1.57e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CREB1—hematologic cancer	1.57e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TERT—hematologic cancer	1.57e-05	0.000199	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—MTR—hematologic cancer	1.57e-05	0.000199	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCG2—hematologic cancer	1.57e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CB—hematologic cancer	1.57e-05	0.000199	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN2B—hematologic cancer	1.56e-05	0.000198	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT1—hematologic cancer	1.55e-05	0.000197	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3R1—hematologic cancer	1.54e-05	0.000195	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ENO2—hematologic cancer	1.54e-05	0.000195	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—CCL2—hematologic cancer	1.54e-05	0.000195	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL6R—hematologic cancer	1.53e-05	0.000194	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PDGFB—hematologic cancer	1.53e-05	0.000194	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3R1—hematologic cancer	1.51e-05	0.000191	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CD86—hematologic cancer	1.51e-05	0.000191	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—JAK2—hematologic cancer	1.5e-05	0.00019	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TSC2—hematologic cancer	1.5e-05	0.00019	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTT1—hematologic cancer	1.49e-05	0.000189	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HES1—hematologic cancer	1.49e-05	0.000188	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NCOR1—hematologic cancer	1.48e-05	0.000187	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—JAK2—hematologic cancer	1.47e-05	0.000186	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGF1—hematologic cancer	1.46e-05	0.000185	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CSF2—hematologic cancer	1.46e-05	0.000185	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAP2K1—hematologic cancer	1.46e-05	0.000185	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—SDC1—hematologic cancer	1.46e-05	0.000185	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—GRB2—hematologic cancer	1.45e-05	0.000184	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CD—hematologic cancer	1.45e-05	0.000184	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFA—hematologic cancer	1.45e-05	0.000184	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FOXO1—hematologic cancer	1.44e-05	0.000183	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FGFR3—hematologic cancer	1.44e-05	0.000183	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—IL2—hematologic cancer	1.44e-05	0.000182	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDGFRB—hematologic cancer	1.44e-05	0.000182	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KITLG—hematologic cancer	1.43e-05	0.000181	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK14—hematologic cancer	1.43e-05	0.000181	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CB—hematologic cancer	1.42e-05	0.00018	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDGFRA—hematologic cancer	1.42e-05	0.000179	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—JAK1—hematologic cancer	1.41e-05	0.000179	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PRKCG—hematologic cancer	1.41e-05	0.000179	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—ESR1—hematologic cancer	1.4e-05	0.000177	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT5A—hematologic cancer	1.4e-05	0.000177	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CB—hematologic cancer	1.39e-05	0.000176	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN2B—hematologic cancer	1.38e-05	0.000175	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FN1—hematologic cancer	1.38e-05	0.000175	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3R1—hematologic cancer	1.37e-05	0.000174	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—BAD—hematologic cancer	1.37e-05	0.000173	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NFKBIA—hematologic cancer	1.37e-05	0.000173	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NOTCH1—hematologic cancer	1.35e-05	0.000171	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CD86—hematologic cancer	1.34e-05	0.00017	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—JAK2—hematologic cancer	1.33e-05	0.000169	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CD80—hematologic cancer	1.33e-05	0.000168	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CG—hematologic cancer	1.32e-05	0.000168	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KIT—hematologic cancer	1.32e-05	0.000168	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—NRAS—hematologic cancer	1.32e-05	0.000168	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HES1—hematologic cancer	1.32e-05	0.000167	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL2RA—hematologic cancer	1.32e-05	0.000167	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NCOR1—hematologic cancer	1.31e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL2—hematologic cancer	1.31e-05	0.000166	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TERT—hematologic cancer	1.3e-05	0.000165	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTPN11—hematologic cancer	1.3e-05	0.000165	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGF1—hematologic cancer	1.3e-05	0.000165	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CSF2—hematologic cancer	1.3e-05	0.000165	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FOXO1—hematologic cancer	1.28e-05	0.000162	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—IL2—hematologic cancer	1.28e-05	0.000162	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFRB—hematologic cancer	1.28e-05	0.000162	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PDGFB—hematologic cancer	1.27e-05	0.000161	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—MAPK3—hematologic cancer	1.27e-05	0.000161	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CB—hematologic cancer	1.27e-05	0.00016	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CREB1—hematologic cancer	1.26e-05	0.00016	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFRA—hematologic cancer	1.26e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—JAK1—hematologic cancer	1.25e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PRKCG—hematologic cancer	1.25e-05	0.000159	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—BRAF—hematologic cancer	1.24e-05	0.000158	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TSC2—hematologic cancer	1.24e-05	0.000158	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CD44—hematologic cancer	1.24e-05	0.000157	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NQO1—hematologic cancer	1.24e-05	0.000157	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCL2—hematologic cancer	1.23e-05	0.000156	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL6R—hematologic cancer	1.23e-05	0.000156	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CREBBP—hematologic cancer	1.23e-05	0.000155	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGFR3—hematologic cancer	1.2e-05	0.000152	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK14—hematologic cancer	1.18e-05	0.00015	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CYCS—hematologic cancer	1.17e-05	0.000149	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAP2K1—hematologic cancer	1.17e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL2RA—hematologic cancer	1.17e-05	0.000148	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	1.17e-05	0.000148	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CD—hematologic cancer	1.16e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL2—hematologic cancer	1.16e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—ESR1—hematologic cancer	1.16e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TERT—hematologic cancer	1.16e-05	0.000147	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—PIK3CA—hematologic cancer	1.15e-05	0.000146	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FN1—hematologic cancer	1.15e-05	0.000145	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—KRAS—hematologic cancer	1.14e-05	0.000144	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—BAD—hematologic cancer	1.13e-05	0.000144	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NFKBIA—hematologic cancer	1.13e-05	0.000144	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PDGFB—hematologic cancer	1.13e-05	0.000143	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NOTCH1—hematologic cancer	1.12e-05	0.000142	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—FGF2—hematologic cancer	1.11e-05	0.000141	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TSC2—hematologic cancer	1.1e-05	0.00014	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CD80—hematologic cancer	1.1e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3R1—hematologic cancer	1.1e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CG—hematologic cancer	1.1e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KIT—hematologic cancer	1.1e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—NRAS—hematologic cancer	1.1e-05	0.000139	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTPN11—hematologic cancer	1.08e-05	0.000137	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—JAK2—hematologic cancer	1.07e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGFR3—hematologic cancer	1.06e-05	0.000135	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK14—hematologic cancer	1.05e-05	0.000133	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—MAPK3—hematologic cancer	1.05e-05	0.000133	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—PIK3CA—hematologic cancer	1.05e-05	0.000133	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CREB1—hematologic cancer	1.05e-05	0.000132	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MDM2—hematologic cancer	1.04e-05	0.000132	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTP1—hematologic cancer	1.03e-05	0.000131	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—BRAF—hematologic cancer	1.03e-05	0.000131	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—ESR1—hematologic cancer	1.03e-05	0.000131	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCL2—hematologic cancer	1.02e-05	0.00013	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL6R—hematologic cancer	1.02e-05	0.000129	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FN1—hematologic cancer	1.02e-05	0.000129	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CREBBP—hematologic cancer	1.02e-05	0.000129	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MTOR—hematologic cancer	1.01e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CB—hematologic cancer	1.01e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—BAD—hematologic cancer	1.01e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NFKBIA—hematologic cancer	1.01e-05	0.000128	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NOTCH1—hematologic cancer	9.97e-06	0.000126	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ABCB1—hematologic cancer	9.8e-06	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CD80—hematologic cancer	9.77e-06	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KIT—hematologic cancer	9.75e-06	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CG—hematologic cancer	9.75e-06	0.000124	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—NRAS—hematologic cancer	9.75e-06	0.000124	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	9.72e-06	0.000123	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—HRAS—hematologic cancer	9.68e-06	0.000123	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	9.65e-06	0.000122	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTPN11—hematologic cancer	9.58e-06	0.000121	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	9.56e-06	0.000121	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1B—hematologic cancer	9.51e-06	0.000121	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—NCOR1—hematologic cancer	9.51e-06	0.00012	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—GSTM1—hematologic cancer	9.51e-06	0.00012	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	9.45e-06	0.00012	CbGpPWpGaD
Midodrine—ADRA1D—GPCR downstream signaling—AKT1—hematologic cancer	9.41e-06	0.000119	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	9.34e-06	0.000118	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CASP3—hematologic cancer	9.32e-06	0.000118	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL2—hematologic cancer	9.31e-06	0.000118	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	9.28e-06	0.000118	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—IL6—hematologic cancer	9.26e-06	0.000117	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	9.24e-06	0.000117	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	9.17e-06	0.000116	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	9.11e-06	0.000115	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	9.08e-06	0.000115	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CCND1—hematologic cancer	9.07e-06	0.000115	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	9.06e-06	0.000115	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—JUN—hematologic cancer	9.06e-06	0.000115	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	9.04e-06	0.000115	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	8.86e-06	0.000112	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—CDKN1A—hematologic cancer	8.78e-06	0.000111	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PTEN—hematologic cancer	8.76e-06	0.000111	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	8.68e-06	0.00011	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	8.65e-06	0.00011	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	8.63e-06	0.000109	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	8.57e-06	0.000109	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK8—hematologic cancer	8.57e-06	0.000109	CbGpPWpGaD
Midodrine—ADRA1D—Signaling by GPCR—AKT1—hematologic cancer	8.55e-06	0.000108	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	8.49e-06	0.000108	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	8.41e-06	0.000107	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	8.41e-06	0.000107	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—MTHFR—hematologic cancer	8.4e-06	0.000106	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	8.39e-06	0.000106	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—EP300—hematologic cancer	8.35e-06	0.000106	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	8.21e-06	0.000104	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—SRC—hematologic cancer	8.12e-06	0.000103	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	8.1e-06	0.000103	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	8.03e-06	0.000102	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	7.91e-06	0.0001	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	7.9e-06	0.0001	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	7.87e-06	9.97e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	7.83e-06	9.92e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	7.81e-06	9.9e-05	CbGpPWpGaD
Midodrine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	7.81e-06	9.9e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	7.74e-06	9.8e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	7.73e-06	9.79e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	7.71e-06	9.77e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	7.69e-06	9.74e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	7.68e-06	9.73e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	7.53e-06	9.54e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	7.52e-06	9.52e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	7.48e-06	9.48e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	7.47e-06	9.47e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	7.47e-06	9.47e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	7.29e-06	9.23e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—MYC—hematologic cancer	7.28e-06	9.22e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	7.27e-06	9.21e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	7.26e-06	9.2e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	7.13e-06	9.04e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	7.11e-06	9.01e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	7.09e-06	8.99e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	7.06e-06	8.95e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	7.01e-06	8.89e-05	CbGpPWpGaD
Midodrine—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	6.94e-06	8.79e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	6.93e-06	8.78e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	6.87e-06	8.71e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL2—hematologic cancer	6.86e-06	8.7e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	6.83e-06	8.65e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	6.74e-06	8.54e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	6.73e-06	8.52e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	6.69e-06	8.48e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—JUN—hematologic cancer	6.68e-06	8.46e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	6.57e-06	8.32e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—CREBBP—hematologic cancer	6.55e-06	8.3e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	6.5e-06	8.24e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	6.49e-06	8.22e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	6.47e-06	8.2e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	6.46e-06	8.18e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	6.32e-06	8e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	6.3e-06	7.98e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	6.21e-06	7.87e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	6.21e-06	7.87e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	6.18e-06	7.83e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—EP300—hematologic cancer	6.16e-06	7.8e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—ALB—hematologic cancer	6.13e-06	7.76e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	6.04e-06	7.65e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	6.03e-06	7.64e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—SRC—hematologic cancer	5.99e-06	7.59e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	5.98e-06	7.57e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	5.86e-06	7.43e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	5.83e-06	7.39e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	5.78e-06	7.32e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	5.76e-06	7.3e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	5.72e-06	7.24e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	5.58e-06	7.07e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	5.52e-06	6.99e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	5.47e-06	6.93e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	5.41e-06	6.86e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—MYC—hematologic cancer	5.37e-06	6.8e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	5.35e-06	6.78e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	5.13e-06	6.5e-05	CbGpPWpGaD
Midodrine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	5.05e-06	6.4e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	4.96e-06	6.29e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	4.96e-06	6.28e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	4.74e-06	6.01e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PTEN—hematologic cancer	4.68e-06	5.92e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	4.56e-06	5.77e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	4.54e-06	5.75e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—EP300—hematologic cancer	4.46e-06	5.65e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—TP53—hematologic cancer	4.41e-06	5.58e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	4.21e-06	5.34e-05	CbGpPWpGaD
Midodrine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	4.19e-06	5.31e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—IL6—hematologic cancer	4.03e-06	5.11e-05	CbGpPWpGaD
Midodrine—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	3.72e-06	4.71e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.3e-06	4.18e-05	CbGpPWpGaD
Midodrine—CYP2D6—Metabolism—AKT1—hematologic cancer	2.69e-06	3.41e-05	CbGpPWpGaD
